Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1248-1249, 2008; 10.1373/clinchem.2007.101204
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lilja, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lilja, H.
Related Collections
Right arrow Citation Classics
(Clinical Chemistry. 2008;54:1248-1249.)
© 2008 American Association for Clinical Chemistry, Inc.

Citation Classic

Testing New PSA Subforms to Enhance the Accuracy of Predicting Cancer Risk and Disease Outcome in Prostate Cancer

Hans Lilja1

1 Departments of Clinical Laboratories, Urology, and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

Address correspondence to the author at: Departments of Clinical Laboratories, Urology, and Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; Email liljah@mskcc.org

The first 20% of the full text of this article appears below.

Featured Article: Lilja H, Christensson A, Dahlen U, et al. Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with {alpha}1-Antichymotrypsin. Clin Chem 1991;37:1618–25.1

Prostate-specific antigen (PSA),2 a kallikrein-like serine protease, is one of the most abundant proteins secreted by the prostate into seminal fluid (1). In the early 1990s, when the study reported in the paper presented here was initiated, serum testing for PSA was coming into widespread use as a means of testing for prostate cancer. Nevertheless, several aspects of PSA in serum remained puzzling; notably, different assays yielded up to 4-fold differences in measured serum PSA concentrations, despite standardization against PSA from seminal fluid.

Before our investigation, PSA in seminal fluid was known to occur as active monomeric peptidase (1), but the nature of PSA in blood remained unclear. We speculated that release of catalytic PSA into an abundance of protease inhibitors in blood could prompt PSA to form inhibitor complexes, similar to the way the digestive enzyme trypsin from the pancreas forms enzyme-inhibitor . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.